SEC Form 3 · accession 0001144204-19-007576
Intec Pharma Ltd. · NTEC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Jan 1, 2019
Accepted (ET)
Feb 14, 2019 · 8:52 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001638381
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | holding | — | — | — | 5,150,848 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Dexcel Pharma Technologies Ltd. ("DPT") and DPT's President and Chief Executive Officer, Dan Oren, are filing this Form 3 because they may be deemed to have beneficial ownership over 5,150,848 ordinary shares (the "Common Shares") of Intec Pharma Ltd. (the "Issuer"). The Common Shares are directly owned by DPT. Mr. Oren is ultimately the sole shareholder of DPT.